Eli Lilly said Monday that its obesity pill Foundayo significantly reduced the severity of obstructive sleep apnea in patients with obesity, according to results from a late-stage trial. Lilly said the results will support a U.S. filing.
The company plans to file with the FDA by the end of the year for approval of the daily pill for moderate-to-severe obstructive sleep apnea in adults with obesity or who are overweight. Foundayo rolled out in the U.S. in April.
The trial tested Foundayo in two studies. The first included 363 patients who were unable or unwilling to use positive airway pressure (PAP) therapy. The second included 349 people who were already using PAP therapy.
In the group not using PAP therapy, patients on Foundayo had an average of 21.1 fewer apnea-hypopnea index (AHI) events per hour at 52 weeks, compared with an average reduction of 4.8 for placebo. Lilly said this equaled an overall AHI reduction of 43.8%, compared with 6.3% for placebo. Lilly said 31.5% of these participants met the criteria for remission or improvement to mild OSA.
In the group using PAP therapy, patients on Foundayo had an average of 18.3 fewer AHI events per hour, compared with 5.5 for placebo. Lilly said this equaled an overall reduction of about 27.5%, compared with 3% for placebo. The company said 19.6% of these participants met the criteria for remission or mild OSA.
Lilly also reported that Foundayo lowered the sleep apnea-specific hypoxic burden, a measure of how deeply and how long oxygen levels fall during sleep, by 55.9% in patients not using PAP and 45.8% in those using it. The company said patients lost roughly 11% of their weight across groups at 52 weeks.
Lilly said the safety profile was generally consistent with earlier trials. About 12% of patients not using PAP discontinued Foundayo due to side effects, compared with 3.8% on placebo. Among patients using PAP, 6.8% discontinued Foundayo, compared with 0.6% on placebo. The most common side effects were gastrointestinal, including nausea, diarrhea, constipation and vomiting, which the company described as generally mild to moderate.
Lilly's Zepbound became the first medication approved in the U.S. for OSA in December 2024, according to the report.